Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Syfovre
Pharma
Apellis' Syfovre faces tough road ahead in GA market: analyst
Despite holding the lead with its complement inhibitor Syfovre, Apellis is discovering that the geographic atrophy market is a tough nut to crack.
Fraiser Kansteiner
May 14, 2025 11:10am
Apellis, AstraZeneca break down their #FierceMadness success
Apr 15, 2025 1:25pm
Apellis expects sales of Syfovre to decline in Q1
Feb 28, 2025 3:05pm
Astellas' Izervay wins key FDA label update after prior rejection
Feb 13, 2025 12:00pm
Astellas takes $760M charge, reveals slowdown for Izervay
Feb 5, 2025 3:22pm
Apellis' weak quarter could signal Syfovre 'nadir': analysts
Nov 5, 2024 3:41pm
